Streetbeat News

Regulatory

CCLD

CareCloud has announced that it expects an improvement of about $10M in annualized free cash flow, representing about 14% of total payroll cost, following a reduction. The information was disclosed in an SEC 8k filing.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:19 pm

CCLD

CareCloud has announced a reduction in its workforce as part of a strategy to align resources with business priorities and improve profitability, according to an SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:18 pm

ALHC

CART

Alignment Healthcare has partnered with Instacart to offer co-branded Medicare Advantage plans in 2024. The initiative aims to make nutritious food more accessible to seniors with chronic illnesses in 13 counties across California and Nevada, pending regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:14 pm

LTRN

Lantern Pharma Inc. (NASDAQ:LTRN) has announced the publication of in vivo data highlighting the enhanced efficacy of its drug candidate LP-184 in glioblastoma (GBM) in Clinical Cancer Research. LP-184 is a unique small molecule that exploits common vulnerabilities in solid tumor and CNS cancers with DNA damage repair (DDR) deficiencies. A Phase 1 clinical trial evaluating LP-184 in patients with advanced solid tumors is underway, with completion expected in the first half of 2024. Lantern estimates that LP-184 has a global aggregate market potential of approximately $11-13 billion.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:11 pm

URGN

UroGen Pharma has announced that it will begin the rolling NDA submission for UGN-102, a treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, in January 2024. This follows a pre-NDA meeting with the FDA.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:10 pm

EFSH

1847 Holdings LLC (NYSE:EFSH) has regained compliance with the NYSE American's continued listing standards. The company is on track to achieve $90 million in sales in 2023 and its cash flow continues to improve. This could allow the company to resume dividends and potentially repurchase stock in the future, subject to establishing a stock buyback plan and future market conditions.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:10 pm

AYRO

AYRO, a US-based electric vehicle manufacturer, has been granted a patent for its user-tailored vehicle seat fabrication technology. This technology allows for customization of vehicle seats based on user preferences, potentially enhancing the user experience and giving AYRO a competitive edge in the EV market.

Portfolio Pulse from Bill Haddad

October 03, 2023 | 12:07 pm

MAIA

MAIA Biotechnology has announced that the FDA has cleared its Investigational New Drug (IND) application for THIO, a first-in-class telomere targeting agent for treating non-small cell lung cancer.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:03 pm

VIR

Vir Biotechnology, Inc. (NASDAQ:VIR) has been awarded approximately $50 million in new funding by the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of novel monoclonal antibody candidates and delivery solutions for COVID-19 and pandemic preparedness and response.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:01 pm

PPH

SPY

The Biden-Harris administration is advancing with plans to negotiate Medicare drug prices in an effort to reduce prescription drug costs for Medicare beneficiaries.

Portfolio Pulse from Charles Gross

October 03, 2023 | 11:56 am